Anti-Neuraminidase Antibodies Reduce the Susceptibility to and Infectivity of Influenza A/H3N2 Virus

3 Gregory Hoy¹, Thomas Cortier^{2,3}, Hannah E. Maier¹, Guillermina Kuan^{4,5}, Roger Lopez^{4,6}, Nery

- 4 Sanchez⁴, Sergio Ojeda⁴, Miguel Plazaola⁴, Daniel Stadlbauer⁷, Abigail Shotwell¹, Angel
- 5 Balmaseda^{4,6}, Florian Krammer^{7,8,9,10}, Simon Cauchemez^{2*}, and Aubree Gordon^{1*}

¹School of Public Health, University of Michigan, Ann Arbor, Michigan, USA; ²Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR 2000 CNRS, Paris, France; ³Collège Doctoral, Sorbonne Université, Paris, France; ⁴Sustainable Sciences Institute, Managua, Nicaragua; ⁵Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua; ⁶Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua ⁷Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA ⁸Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁹Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁰Ignaz Semmelweis Institute,

- 13 Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁰Ignaz Semmelweis Ins 14 Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria
- 15 *Denotes co-senior authors

16 17 **Abstract**

6

7

8

9

10

11

12

Immune responses against neuraminidase (NA) are of great interest for developing more 18 19 robust influenza vaccines, but the role of anti-NA antibodies on influenza infectivity has not been established. We conducted household transmission studies in Managua, Nicaragua to examine 20 the impact of anti-NA antibodies on influenza A/H3N2 susceptibility and infectivity. Analyzing 21 22 these data with mathematical models capturing household transmission dynamics and their drivers, we estimated that having higher preexisting antibody levels against the hemagglutinin 23 (HA) head, HA stalk, and NA was associated with reduced susceptibility to infection (relative 24 susceptibility 0.67, 95% Credible Interval [Crl] 0.50-0.92 for HA head; 0.59, 95% Crl 0.42-0.82 25 for HA stalk; and 0.56, 95% Crl 0.40-0.77 for NA). Only anti-NA antibodies were associated with 26 27 reduced infectivity (relative infectivity 0.36, 95% Crl 0.23-0.55). These benefits from anti-NA 28 immunity were observed even among individuals with preexisting anti-HA immunity. These 29 results suggest that influenza vaccines designed to elicit NA immunity in addition to

30 hemagglutinin immunity may not only contribute to protection against infection but reduce

- 31 infectivity of vaccinated individuals upon infection.
- 32
- 33
 34
 35
 36
 37
 38
 39
 40
- -0
- 41

42 Introduction

Influenza virus infection remains an important cause of human disease burden, 43 with upwards of one billion infections and up to 650,000 deaths occurring globally every 44 year from disease caused by the influenza virus¹. Vaccination against influenza virus is 45 46 one of the most effective approaches for reducing the overall morbidity and mortality of seasonal influenza in communities, and improving the effectiveness of influenza 47 vaccines is an important goal²⁻⁵. There are two important components of transmission; 48 49 susceptibility refers to an individual or group's propensity to become infected with influenza, assuming adequate exposure. *Infectivity* refers to an individual or group's 50 propensity to infect others, assuming that they themselves are infected. Conditional on 51 the first person already being infected, the overall risk of transmission from one person 52 to another depends on the infectivity of the first person and the susceptibility of the 53 second. Much of the effort for influenza vaccine improvement has focused on the 54 induction of immune responses that reduce susceptibility to infection or disease, to 55 moderate effectiveness; much less attention has been given to the development of 56 57 vaccines that reduce individual-level infectivity among the vaccinated; in other words, vaccines that generate an immune response that decreases the infectivity of vaccinees, 58 even if they are not fully protected from infection^{3,4,6–8}. Population-level vaccination 59 60 efforts clearly reduce overall community transmission, likely because vaccinated individuals show reduced susceptibility to infection, which breaks transmission chains⁹⁻ 61 62 ¹¹. However, there is no evidence that current-generation influenza vaccines reduce individual-level infectivity directly, and little is known about if and how immune 63 responses that protect against influenza virus infection affect individual infectivity. The 64 identification of immune responses that both reduce susceptibility to infection and 65

reduce infectivity among vaccinated individuals who are infected would allow for the 66 development of influenza vaccinations that lower overall influenza circulation in 67 communities and that provide additional indirect protection to individuals who are 68 unvaccinated or under vaccinated for influenza, including infants and 69 immunocompromised individuals. 70 71 Antibody responses against neuraminidase (NA), an influenza surface glycoprotein, are thought to protect against severe disease caused by the influenza 72 73 virus, and high pre-infection anti-NA antibody levels have been shown to reduce the overall duration of influenza viral shedding^{12–19}. Additionally, studies in animal models 74 have demonstrated a reduction in viral shedding occurring in animals immunized 75 against neuraminidase^{20,21}. However, viral shedding does not always consistently 76 correlate with infectivity, and direct transmission reduction of anti-NA immunity has not 77 been demonstrated in human populations²². Additionally, the role of the anti-NA 78 79 response on infectivity, relative to other important immune targets such as hemagglutinin, has not been investigated. This study aims to explore the impact of pre-80 existing antibody levels against the hemagglutinin (HA) head, HA stalk, and NA on 81 82 influenza virus A/H3N2 transmission in a household setting, with particular interest in the role of anti-neuraminidase responses in modulating transmission risk. 83

84

85 **Results**

86 Participant and household characteristics

Over three influenza seasons (2014, 2016, 2017), a total of 171 households (171 index cases and their 664 households contacts) were recruited following the detection of an infected individual (i.e. the index case) and followed up for an average duration of

36.7 days. 148 out of 664 (22.3%) household contacts were infected during the follow-90 up period. Households were enrolled through identification of an index case at the study 91 clinic (2014, 2016), or pre-enrolled households were activated after detection of 92 influenza virus via polymerase chain reaction (PCR) in a member of an enrolled 93 household (2017). Once activated, index cases and household contacts were tested for 94 95 influenza virus every 2-3 days using PCR, and serology was done on blood samples collected on the first day of household activation (the initial/acute sample) and 30-45 96 97 days after household activation (the final/convalescent sample). More information about the study design and case ascertainment is available in the Online Methods. The 98 number of infections per household ranged from 1 to 10, with an average of 1.87 total 99 100 infections and 0.87 secondary infections per household. The serial interval (i.e. the average time between index case onset and onset of cases in household contacts) was 101 102 3.4 days (SD 2.8 days). A visualization of the intensive monitoring periods by household 103 is presented in Figure 1.

Less than 10% of individuals had ever been vaccinated against influenza, and 104 only two individuals had been vaccinated for influenza in the 6 months prior to the start 105 106 of the monitoring period. Positive individuals were younger. Overall, a higher proportion of infected individuals had anti-HA head, HA stalk, and NA pre-existing antibody levels 107 108 in the lower quartiles when compared to uninfected individuals (Table 1). There was no 109 difference in the pre-existing antibody levels between index cases and secondary cases for hemagglutination inhibition assay titers (HAI) and HA stalk antibody levels; however, 110 111 index cases had slightly lower anti-NA antibody levels when compared to secondary 112 cases (median AUC 29.7 and 45.4, respectively, p = 0.042) (Figure 2a). The secondary

attack rate in households with an index case with low-to-undetectable anti-NA
antibodies was 23.4%, compared to 17.1% in households with an index case with
higher anti-NA antibodies (p=0.15); there was no difference in secondary attack rates in
households by index case anti-HA head or anti-HA stalk antibodies (Figure 2b).

117 Effect of pre-existing antibody levels on susceptibility and infectivity

118 A mathematical model, calibrated to the data with Bayesian data augmentation methods, was used to reconstruct the unobserved chains of transmission accounting for 119 the possibility of community (i.e. household member infected outside the household) 120 121 and tertiary (i.e. household member infected by another household member who is not the index case) infections, estimate household transmission rates and determine factors 122 affecting individual relative susceptibility and infectivity (see Online Methods)²³. 123 Compared to adults 15+ years of age, children aged 0-14 years had higher relative 124 susceptibility (relative susceptibility 1.63, 95% Crl 1.22-2.18). High initial antibody levels 125 against the HA head (0.67, 95% Crl 0.50-0.92), HA stalk (0.59, 95% Crl 0.42-0.82), and 126 NA (0.56, 95% Crl 0.40-0.77) were associated with reduced susceptibility to influenza 127 A/H3N2 virus infection (Figure 3a). In infected A/H3N2 individuals, high initial antibody 128 129 levels against NA were associated with reduced infectivity (relative infectivity 0.36, 95%) Crl 0.23-0.55). In contrast, high initial antibody levels against the HA head and the HA 130 131 stalk were not associated with reduced infectivity (1.33, 95% Crl 0.90-1.90 for the HA 132 head, 1.08, 95% CrI 0.75-1.59 for the HA stalk)(Figure 3b). The probability of infection from the community was estimated to be 5.8% per month (95% Crl 2.7%-10.8%). 133

134

136 Necessity of robust antibody responses to reduce susceptibility

Because antibodies against all three antigens were associated with reduced 137 138 susceptibility, we next explored whether high antibody levels against a single antigen could significantly impact susceptibility and infectivity, or whether a combination of 139 immune responses was needed. We therefore compared the A/H3N2 susceptibility and 140 141 infectivity of individuals who had high antibody levels for zero antibody measures, one antibody measure, two antibody measures where none are against NA, and two or more 142 143 antibody measures where one is against NA. This model allows us to test the hypothesis of an additive protective effect of anti-HA head, anti-HA stalk and anti-NA 144 antibodies made in our baseline model, as well as any dose-response pattern observed 145 in the relationship between antibody levels and susceptibility/infectivity. Furthermore, by 146 splitting the high-responder categories by those with anti-NA antibodies and those with 147 low-to-undetectable anti-NA antibodies, we are able to further test whether anti-NA 148 149 immunity is uniquely associated with reduced infectivity in influenza virus A/H3N2. 150 Individuals with higher antibody levels for one measure did not see their susceptibility or infectivity modified compared to individuals with low antibody levels for all measures 151 152 (relative susceptibility 0.83, 95% Crl 0.49-1.38; relative infectivity 0.95, 95% Crl 0.56-1.52), nor did individuals with higher antibody levels for both the anti-HA measures 153 154 (relative susceptibility 0.62, 95% Crl 0.34-1.10; relative infectivity 1.17, 95% Crl 0.62-155 2.03). However, individuals with high antibody levels for two or more measures, one of which is a response against NA, demonstrate reduced susceptibility to and infectivity of 156 157 influenza virus A/H3N2 (relative susceptibility 0.32, 95% Crl 0.21-0.48; relative 158 infectivity 0.46, 95% Crl 0.29-0.70)(Figure 4).

159 Effect of anti-NA antibodies in individuals with existing anti-HA antibodies

Finally, we asked whether the benefit of anti-NA immunity was only seen in those 160 with little-to-no anti-HA immunity, or whether anti-NA immunity was beneficial even in 161 individuals with high pre-existing antibody levels to HA. To do this, we investigated the 162 relative contribution of anti-NA antibody levels on influenza virus A/H3N2 infections 163 164 among individuals who have existing high anti-HA antibodies to understand what, if any, benefit that high anti-NA antibodies have on susceptibility and infectivity among 165 individuals who already have some anti-HA immunity. Among individuals with high anti-166 167 HA head and/or anti-HA stalk preexisting antibodies, those who also had higher anti-NA antibody levels had reduced susceptibility (relative susceptibility 0.43, 95% CrI 0.30-168 0.61) and infectivity (relative infectivity 0.42, 95% Crl 0.27-0.67) to influenza A/H3N2 169 virus infection, relative to those with low anti-NA antibody levels. 170

171

172 Simulation analyses

173 Simulating epidemics in households from the model, we found that the transmission model was able to capture the observed patterns of secondary attack rates 174 (SARs) by household size, even among large households (Supplemental Figure 1). In 175 176 households of size 4, the most common household size in this study, the observed SAR was 0.18, and the estimated SAR across 100 simulations was 0.19 (95% Crl 0.14-0.26). 177 When we used our inference framework on data simulated from our model with 178 known parameter values, parameter values were recovered consistently and with little 179 directional bias. The simulation value fell within the 95% credible interval in 85%+ of 180 simulations for all parameters, except for the NA infectivity parameter (70%) (Figure 5). 181 In sensitivity analyses, we checked that the association between higher anti-NA 182

antibody levels and reduced infectivity remains under different assumptions about
 distribution of the incubation and infectivity periods (Supplemental Table 1).

185 **Discussion**

Through intensive monitoring of households with known influenza A/H3N2 virus infection in combination with statistical transmission modeling, this study was able to reconstruct household transmission chains and assess the impact of individual-level factors, such as pre-existing antibody levels, on the susceptibility and infectivity of influenza A/H3N2 virus in a household setting.

Individuals who were infected with influenza A/H3N2 virus and who had high pre-191 existing antibodies against NA demonstrated reduced infectivity relative to infected 192 individuals with low preexisting antibodies against NA. The magnitude of this difference 193 194 is substantial, with high-anti-NA individuals having 64% (95% Crl 40-79%) reduced infectivity compared to low-anti-NA individuals. Importantly, preexisting antibodies 195 against the HA head and HA stalk were not associated with reduced infectivity. 196 197 indicating that a reduction in influenza infectivity may depend on anti-NA responses 198 alone. This specificity is biologically plausible, as NA, not HA, is responsible for viral 199 egress, and thus it is reasonable that anti-NA responses alone contribute to a reduction in overall viral load, viral shedding, and subsequent transmission¹⁶. 200

We found that all the factors of interest included in the transmission model, namely age and pre-existing antibody levels against the HA head, HA stalk, and NA, were associated with influenza susceptibility. Specifically, children aged 14 years and younger were 63% more susceptible to infection than adults aged 15 years and older. This is in line with a large body of work indicating that children are more susceptible to influenza virus infection but suggests that this susceptibility is not entirely due to a lack of influenza exposure history and immune response, as we observe a large association
between age and susceptibility even when accounting for anti-HA head, anti-HA stalk,
and anti-NA antibody levels^{22,24–28}. Individuals with high preexisting antibodies
demonstrated reduced susceptibility to influenza A/H3N2 virus infection, with reductions
of 33%, 41%, and 44%, respectively, for antibodies against the HA head, HA stalk, and
NA, which is in line with previous work on the correlates of protection against influenza
viruses, including influenza A/H3N2^{12,13,29,30}.

We found that susceptibility to and the infectivity of influenza A/H3N2 virus was 214 215 not reduced when individuals had higher antibodies for only one target (HA head, HA stalk, or NA), nor were they reduced when individuals had higher antibodies for multiple 216 217 HA targets but not NA. However, having higher antibodies for two or more targets, with one being NA, was associated with a 68% (52%-79%) reduction in susceptibility and 218 54% (30%-71%) reduction in infectivity, respectively, compared to individuals with low-219 220 to-undetectable antibodies against all targets. These findings emphasize the importance of generating robust, multi-epitope immune responses in vaccine-development efforts to 221 generate vaccinations that protect adequately against infection and transmission. They 222 223 also suggest that the induction of robust anti-NA immunity may be especially important. Among individuals with existing immunity to HA, high anti-NA antibody levels are 224 225 associated with a reduction in influenza A/H3N2 virus infectivity and susceptibility, 226 indicating that the induction of better anti-NA response may be beneficial even in individuals with strong anti-HA immunity. Though current-generation influenza vaccines 227 228 typically include a neuraminidase component, the immunogenicity of the NA component 229 of vaccines is inconsistent, and anti-NA responses are often not utilized as an endpoint

in the projection of vaccine efficacy against seasonal influenza^{5,31}. These results
 suggest that, to generate next-generation influenza vaccines that are effective at
 reducing susceptibility as well as infectivity, the anti-NA response generated by vaccine
 candidates needs to be emphasized, measured, and assessed.

The secondary attack rate (the proportion of household contacts that become 234 235 infected) in the study population was 22.3%, which is consistent with that found from other studies, especially given that there is a large proportion of children who have been 236 associated with higher influenza SARs, in this population relative to that of other 237 studies^{28,32}. As expected, individuals who remained negative for influenza A/H3N2 virus 238 throughout the monitoring period had higher initial levels for antibodies against the HA 239 240 head, HA stalk, and NA when compared to individuals who became positive. Index cases had a similar distribution of pre-existing antibody levels compared to secondary 241 cases for anti-HA head and stalk antibodies, indicating that there is likely not a large bias 242 243 in the ascertainment of index cases vs. secondary cases relative to preexisting antibody levels. The small difference in distribution observed for NA may be due to differing age 244 and symptom distributions between index cases and secondary cases. 245

This study is strengthened by the relatively large sample size, robust immunologic characterization of participants before and after infection, and methods that allow for probabilistic chains of transmission to be reconstructed to assess individual-level risk factors for infectivity and susceptibility, rather than assuming all secondary cases arise from the index case. Furthermore, the unvaccinated nature of the population allows us to specifically examine infection-induced immunity.

This study is limited by the low number of vaccinated participants, which makes 252 stratification by vaccination status impossible; the relative contribution of anti-NA 253 254 antibodies on A/H3N2 transmission may differ between vaccine-induced and infectioninduced immunity in ways that we cannot assess. Furthermore, even though our 255 modelling accounts for the possibility of community infections, we cannot rule out the 256 257 possibility that some household contacts infected in the community might have been misattributed to in-household transmission; however, we would not expect this to be 258 259 specific to higher or low-to-undetectable antibody levels for any of the targets and would not expect a directional bias in these estimates. 260

261 **Conclusions**

Using data from two large household transmission studies, we found that, though 262 pre-existing anti-HA head, stalk, and anti-NA antibodies are important for reduced 263 susceptibility to influenza A/H3N2 virus infection, only anti-NA antibodies are associated 264 with reduced infectivity in a household transmission setting. Our results suggest that the 265 266 induction of a better humoral immune response against NA may improve next-267 generation vaccines' effectiveness at preventing infection and disease and may reduce individual infectivity even in the event of a breakthrough infection. These findings 268 reinforce the need for continued development of influenza vaccinations that target NA in 269 270 addition to HA in order to develop next-generation influenza vaccines that protect against influenza virus infection and reduce influenza infectivity. 271 272 273

274

276 Online Methods

277 Study Population and Design

278 This study uses data from two household influenza transmission studies based in Managua, Nicaragua: the Household Influenza Transmission Study (HITS) and the 279 280 Household Influenza Cohort Study (HICS). HITS is a case-ascertained study, meaning that influenza-positive individuals are identified, and other members of their household 281 recruited for enrollment, that ran from 2012 to 2017, and HICS is a prospective 282 household-based cohort study that began in 2017 and is currently ongoing. In both 283 studies, influenza A/H3N2 virus-positive individuals, the index cases, are initially 284 detected at a health center, where household members are enrolled (HITS) or activated 285 (HICS) into intensive monitoring for a period of ~14 days. During this period, household 286 members are tested repeatedly for influenza virus, allowing for a reconstruction of likely 287 transmission chains within each household. Blood samples are collected both at the 288 beginning of the monitoring period and 30-45 days after³³. These studies were approved 289 by the institutional review boards at the Nicaraguan Ministry of Health and the University 290 of Michigan and are in accordance with the Helsinki Declaration of the World Medical 291 292 Association. Written consent to participate or parental permission was obtained for all participants; in children older than 6 years, verbal assent was obtained. 293

294 Laboratory Methods

Nasal/oropharyngeal swabs collected from household members were tested for
influenza virus with real-time reverse-transcription polymerase chain reaction (RT-PCR)
using validated Centers for Disease Control and Prevention (CDC) protocols. If positive
for influenza virus, subtype or lineage determination was performed using additional RTPCR assays^{34–36}. Several serological assays were conducted on each blood sample to

measure the initial and final antibody levels against various influenza antigens; 300 hemagglutination inhibition assays (HAIs), and enzyme-linked immunosorbent assays 301 302 (ELISAs) against full-length HA, the HA stalk, and NA. Details about the specific antigens used for each assay are available in the supplement (Supplemental Table 2). 303 **Statistical Methods** 304 Preexisting antibody levels were divided into quartiles, with the lowest quartile 305 corresponding to low antibody levels and the remaining quartiles corresponding to high 306 307 antibody levels. The distribution of initial antibody levels for index cases, secondary infections within the household of the index case, and uninfected household members 308 were compared using two-sided Wilcoxon rank-sum tests. 309

We used a mathematical model to assess the impact of individual-level age and 310 311 immune characteristics and contact structure on the person-to-person probability of transmission. The model estimated the risk of transmission between all household 312 members including the risk from secondary cases. The risk of transmission from an 313 infected individual depended on time after infection with by lognormal distribution^{23,37,38}. 314 315 This risk was modulated by infectivity factors, namely individual pre-existing anti-HA 316 head, anti-HA stalk, and anti-NA antibody levels of the infector. It was also modulated 317 by the susceptibility factors being the individual characteristics of the susceptible 318 contact, namely individual age and pre-existing anti-HA head, anti-HA stalk, and anti-NA 319 levels. Finaly the risk depended on the household size. We also estimated the risk of 320 infection from the community. This transmission model accounts for chains of transmission within households, namely that additional household infections beyond the 321 index case may occur due to community transmission or due to infection from a non-322 323 index household member, which is advantageous relative to other common statistical

approaches to transmission, approaches including logistic models^{23,24,39,40}. Additional

information about the transmission model, including the functional forms and

mathematical formalism, are included in the Supplement.

327 Model parameters were estimated using Bayesian Markov chain Monte Carlo

328 (MCMC)^{23,41}. The statistical model has a hierarchical structure with three levels²³: i) the

329 observation level ensures consistency between observed and augmented data (based

on the probabilistic distribution assumed for the incubation period^{23,41–43}), ii) the

transmission model (described above), characterizes within household transmission

332 dynamics, iii) the prior model describe prior distribution for model parameters.

333 Transmission parameters and augmented times of infection were iteratively updated

using a Metropolis-Hastings algorithm^{23,41–45}. Each MCMC chain was iterated 50,000

times, and the first 500 iterations were burned out. We report the median of the

posterior distribution with the 95 credible interval (Crl) for each estimated transmissionparameter.

Additionally, 100 datasets of simulated infection events were generated by an 338 agent-based model by retaining household structure, index case assignment, and 339 340 individual characteristics such as age and antibody levels. Infection events at each time step were drawn randomly from the probability of transmission derived from the 341 342 transmission model. Transmission parameters used were the posterior medians. We 343 assessed model adequacy by comparing secondary attack rates at each household size generated by the model to those generated by the observed data, and examined the 344 345 bias of estimated parameters, including the proportion of the 95% credible interval from 346 the original posterior distributions that covered the median simulation values. Analyses

347	were conducted using SAS 9.4, R version 4.3.1-4.3.2, and Visual Studio Code version
348	1.87.2
349	
350	
351	
352	
353	
354	
355	
356	
357	
358	
359	
360	
361	
362	
363	
364	
365	
366	
367	
368	
369	
370	
371	
372	
373	
374	

375 Tables

376 **Table 1. Description of Study Population**

	A/H3N2 positive	A/H3N2 negative	Total (n=835)
	n (%)	n (%)	n (%)
Gender			
Female	176 (55.2)	342 (66.3)	518 (62.0)
Male	143 (44.8)	174 (33.7)	317 (38.0)
Age (mean, SD)	14.7 (14.9)	27.1 (19.0)	22.3 (18.6)
0-1 year	27 (8.5)	9 (1.7)	36 (4.3)
2-4 years	66 (20.7)	32 (6.2)	98 (11.7)
5-14 years	120 (37.6)	147 (28.5)	267 (32.0)
15+ years	106 (33.2)	328 (63.6)	434 (52.0)
Vaccination			
Ever vaccinated	40 (12.5)	36 (7.0)	76 (9.1)
Recently	2 (0.6)	0 (0.0)	2 (0.2)
Vaccinated*			
Season			
2014-2015	44 (13.8)	90 (17.4)	134 (16.0)
2016-2017	122 (38.2)	164 (31.8)	286 (34.3)
2017-2018	153 (48.0)	262 (50.8)	415 (49.7)
НАІ			
Quartile 1	122 (38.2)	143 (27.7)	265 (31.7)

Quartile 2	74 (23.2)	107 (20.7)	181 (21.7)			
Quartile 3	92 (28.8)	171 (33.1)	263 (31.5)			
Quartile 4	31 (9.7)	95 (18.4)	126 (15.1)			
HA stalk						
Quartile 1	117 (36.7)	91 (17.6)	208 (24.9)			
Quartile 2	89 (27.9)	123 (23.8)	212 (25.4)			
Quartile 3	61 (19.1)	142 (27.5)	203 (24.3)			
Quartile 4	52 (16.3)	160 (31.0)	212 (25.4)			
NA						
Quartile 1	128 (40.1)	83 (16.1)	211 (25.3)			
Quartile 2	79 (24.8)	130 (25.2)	209 (25.0)			
Quartile 3	64 (20.1)	144 (27.9)	208 (24.9)			
Quartile 4	48 (15.1)	159 (30.8)	207 (24.8)			
Vaccinated within 6 months of the start of the intensive monitoring period.						





Figure 1. Intensive monitoring periods by household. Infected individuals represented with red dots; uninfected individuals are represented in blue dots. The blue bars represent the duration of the influenza intensive monitoring period within the household.

385			
386			
387			
388			
389			
390			
391			

medRxiv preprint doi: https://doi.org/10.1101/2024.06.14.24308936; this version posted June 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 2. Antibody levels by PCR status and household SAR. (a) Distribution of pre-infection antibody titers by PCRnegative individuals, probable index cases, and probable secondary/tertiary cases (chevrons representing mean antibody level). (b) Mean and 95% confidence intervals for the secondary attack rates by household, stratified by the antibody levels of the household index case. P-values are calculated from generalized estimating equations (GEEs) with weighting by household size.

395			
396			
397			
398			



Figure 3. Relative susceptibility and infectivity of A/H3N2 by age and antibody levels (a) Point estimate and 95% credible interval for relative susceptibility to A/H3N2 as a function of age and high versus low initial antibody levels against the HA head, HA stalk, and NA. (b)) Point estimate and 95% credible interval for relative infectivity of A/H3N2 as a function of high versus low initial antibody levels against the HA head, HA stalk, and NA.

399			
400			
401			
402			
403			



404

Figure 4. Effect of cumulative antibody levels on susceptibility and infectivity Point estimate and 95% credible interval for (a) relative susceptibility to A/H3N2 as a function of age and categorical higher-versus-low antibody levels for zero (reference), one, two or more (not including NA), or two or more (including NA) antibody targets, and (b) relative infectivity of A/H3N2 as a function of categorical, higher-versus-low antibody levels for zero (reference), one, two or more (including NA) antibody targets.

405		
406		
407		
408		
409		
410		
411		
412		



Figure 5. Parameter estimates in simulated datasets. (a) Point estimate and 95% credible interval for each parameter from the actual data, compared to the parameter point estimates recovered from running the MCMC on each simulated dataset. (b) proportion of simulations where the parameter point estimates recovered from the simulated dataset falls within the 95% credible interval of the parameters run on the actual data. Alpha is the community transmission parameter, beta is the household transmission parameter, and delta is a parameter for relating beta to household size.

415			
416			
417			
418			

419 Acknowledgements

This work was supported by the National Institutes of Allergy and Infectious Diseases 420 through the Collaborative Influenza Vaccine Innovation Centers [75N93019C00051 to 421 422 F.K. and A.G.]the St. Jude Center of Influenza Research and Surveillance [HHSN272201400006C to A.G.]; the St. Jude Center of Excellence for Influenza 423 424 Research and Response [75N93021C00016 to A.G.]and grant R01 Al120997 to A.G. 425 Aubree Gordon is supported by the Biosciences Initiative at the University of Michigan 426 through a Mid-career Biosciences Faculty Achievement Award (MBioFAR). S.C. 427 acknowledges support by the European Commission under the EU4Health programme 428 2021-2027, Grant Agreement - Project: 101102733 — DURABLE, the Laboratoire 429 d'Excellence Integrative Biology of Emerging Infectious Diseases program (grant ANR-430 10-LABX-62-IBEID) the European Union's Horizon 2020 research and innovation 431 programme under VEO grant agreement No. 874735, and the INCEPTION project (PIA/ANR16-CONV-0005). The funding agencies had no role in the design and conduct 432 433 of the study, collection, management, analysis or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for 434 publication. 435

436

We thank the study participants and the many dedicated study personnel in Nicaragua
at the Centro Nacional de Diagnóstico y Referencia and the Sócrates Flores Vivas

439 Health Center.

440

441 Author Contributions

Gregory Hoy: Data curation; formal analysis; methodology; software; validation; 442 visualization: writing—original draft: writing—review and editing. Thomas Cortier: formal 443 444 analysis; methodology; software; validation; visualization; writing-original draft; writingreview and editing. Hannah E. Maier: data curation; methodology; software; validation; 445 visualization; writing-review and editing. Guillermina Kuan: Investigation; project 446 447 administration; writing-review and editing. Roger Lopez: Investigation; writing-review and editing. Nery Sanchez: Investigation; writing-review and editing. Sergio Ojeda: 448 Investigation; project administration; writing-review and editing. Miguel Plazaola: 449 450 Investigation; project administration; writing-review and editing. Daniel Stadlbauer: 451 Data curation; writing-review and editing. Abigail Shotwell: data curation; writing-452 review and editing. Angel Balmaseda: Investigation; methodology; supervision; project administration; writing—review and editing. Florian Krammer: funding acquisition; 453 454 investigation; ; supervision; writing-review and editing. Simon Cauchemez: 455 Conceptualization; investigation; methodology; project administration; resources; supervision; writing—review and editing. Aubree Gordon: Conceptualization; funding 456 acquisition; investigation; methodology; project administration; resources; supervision; 457 458 writing-review and editing.

459

460 **Conflict of interest statement**

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to 461 SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus 462 vaccines and influenza virus therapeutics which list Florian Krammer as co-inventor. 463 Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-464 2 and another company, CastleVax, to develop SARS-CoV-2 vaccines. Florian Krammer 465 is a co-founder and scientific advisory board member of CastleVax. Florian Krammer has 466 467 consulted for Merck, Curevac, Seqirus, GSK and Pfizer and is currently consulting for 3rd Rock Ventures, Gritstone and Avimex. The Krammer laboratory is collaborating with 468 469 Dynavax on influenza vaccine development. Aubree Gordon has served on an RSV 470 vaccine advisory board for Janssen.

471 Inclusion and ethics in global research statement

This study has included local researchers throughout the research process and is locally relevant as determined in partnership with local partners. Roles and responsibilities were

agreed upon amongst collaborators ahead of the research, including capacity building for

local researchers. This research was approved by the Nicaraguan Ministry of Health.

476

477 Data availability statement

478

- The data that support the findings of this study are available from the corresponding
- 480 author upon reasonable request and following IRB approval.

481

482 Code availability statement

- 483 Code supporting the findings of this research can be found at
- 484 https://github.com/gehoy/H3N2_NA_transmission.

485

486

487

488

489

490

492

493 **References**

494

495 1. WHO launches new global influenza strategy. https://www.who.int/news/item/11 496 03-2019-who-launches-new-global-influenza-strategy.

Belongia, E. A. *et al.* Variable influenza vaccine effectiveness by subtype: a
systematic review and meta-analysis of test-negative design studies. *Lancet Infect Dis* **16**, 942–951 (2016).

Berlanda Scorza, F., Tsvetnitsky, V. & Donnelly, J. J. Universal influenza
 vaccines: Shifting to better vaccines. *Vaccine* 34, 2926–2933 (2016).

502 4. Doherty, P. C. & Kelso, A. Toward a broadly protective influenza vaccine. *J Clin* 503 *Invest* **118**, (2008).

504 5. Krammer, F. *et al.* NAction! How Can Neuraminidase-Based Immunity Contribute 505 to Better Influenza Virus Vaccines? *mBio* **9**, e02332-17 (2018).

506 6. Nachbagauer, R. *et al.* A universal influenza virus vaccine candidate confers
507 protection against pandemic H1N1 infection in preclinical ferret studies. *npj Vaccines* 2,
508 1–13 (2017).

509 7. Past Seasons Vaccine Effectiveness Estimates | CDC.

510 https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html (2022).

8. Paules, C. I., Marston, H. D., Eisinger, R. W., Baltimore, D. & Fauci, A. S. The Pathway to a Universal Influenza Vaccine. *Immunity* **47**, 599–603 (2017).

513 9. Nichol, K. L. Efficacy and effectiveness of influenza vaccination. *Vaccine* **26**, 514 D17–D22 (2008).

Jackson, C., Vynnycky, E., Hawker, J., Olowokure, B. & Mangtani, P. School
closures and influenza: systematic review of epidemiological studies. *BMJ Open* 3,
e002149 (2013).

Jordan, R. *et al.* Universal vaccination of children against influenza: are there
indirect benefits to the community? A systematic review of the evidence. *Vaccine* 24,
1047–1062 (2006).

12. Monto, ArnoldS. & Kendal, AlanP. EFFECT OF NEURAMINIDASE ANTIBODY
ON HONG KONG INFLUENZA. *The Lancet* **301**, 623–625 (1973).

Monto, A. S. *et al.* Antibody to Influenza Virus Neuraminidase: An Independent
 Correlate of Protection. *The Journal of Infectious Diseases* **212**, 1191–1199 (2015).

525 14. Giurgea, L. T., Morens, D. M., Taubenberger, J. K. & Memoli, M. J. Influenza
526 Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine.
527 *Vaccines (Basel)* 8, 409 (2020).

Maier, H. E. *et al.* Pre-existing Antineuraminidase Antibodies Are Associated
With Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in
Naturally Infected Adults. *Clinical Infectious Diseases* **70**, 2290–2297 (2020).

16. Bouvier, N. M. & Palese, P. THE BIOLOGY OF INFLUENZA VIRUSES. *Vaccine* 532 26, D49–D53 (2008).

533 17. McMahon, M. *et al.* Immunity induced by vaccination with recombinant influenza 534 B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an 535 exposure intensity-dependent manner. *J Virol* **97**, e0105723 (2023).

Tan, J. *et al.* Murine Broadly Reactive Antineuraminidase Monoclonal Antibodies
Protect Mice from Recent Influenza B Virus Isolates and Partially Inhibit Virus
Transmission in the Guinea Pig Model. *mSphere* 7, e0092721 (2022).

Tan, J. *et al.* Human Anti-neuraminidase Antibodies Reduce Airborne
Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model. *J Virol* 96,
e0142121 (2022).

542 20. Romagosa, A. *et al.* Vaccination of influenza a virus decreases transmission 543 rates in pigs. *Vet Res* **42**, 120 (2011).

544 21. McMahon, M. *et al.* Mucosal Immunity against Neuraminidase Prevents Influenza
545 B Virus Transmission in Guinea Pigs. *mBio* 10, e00560-19 (2019).

546 22. Tsang, T. K. *et al.* Individual Correlates of Infectivity of Influenza A Virus
547 Infections in Households. *PLOS ONE* **11**, e0154418 (2016).

- 548 23. Cauchemez, S., Carrat, F., Viboud, C., Valleron, A. J. & Boëlle, P. Y. A Bayesian
 549 MCMC approach to study transmission of influenza: application to household
 550 longitudinal data. *Stat Med* 23, 3469–3487 (2004).
- 551 24. Tsang, T. K. *et al.* Influenza A Virus Shedding and Infectivity in Households. *J* 552 *Infect Dis* **212**, 1420–1428 (2015).
- 25. Nayak, J., Hoy, G. & Gordon, A. Influenza in Children. *Cold Spring Harb Perspect Med* a038430 (2019) doi:10.1101/cshperspect.a038430.
- 26. Cauchemez, S. *et al.* Determinants of Influenza Transmission in South East Asia:
 Insights from a Household Cohort Study in Vietnam. *PLOS Pathogens* **10**, e1004310
 (2014).
- 558 27. Mettelman, R. C. & Thomas, P. G. Human Susceptibility to Influenza Infection 559 and Severe Disease. *Cold Spring Harb Perspect Med* **11**, a038711 (2021).

Huang, Q. S. *et al.* Risk Factors and Attack Rates of Seasonal Influenza
Infection: Results of the Southern Hemisphere Influenza and Vaccine Effectiveness
Research and Surveillance (SHIVERS) Seroepidemiologic Cohort Study. *J Infect Dis* **219**, 347–357 (2019).

564 29. Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum 565 haemagglutination-inhibiting antibody in protection against challenge infection with 566 influenza A2 and B viruses. *Epidemiology & Infection* **70**, 767–777 (1972).

30. Ng, S. *et al.* Novel correlates of protection against pandemic H1N1 influenza A
virus infection. *Nat Med* 25, 962–967 (2019).

569 31. Weir, J. P. & Gruber, M. F. An overview of the regulation of influenza vaccines in 570 the United States. *Influenza and Other Respiratory Viruses* **10**, 354–360 (2016).

571 32. Azman, A. S. *et al.* Household transmission of influenza A and B in a school-572 based study of non-pharmaceutical interventions. *Epidemics* **5**, 181–186 (2013).

33. Gordon, A. *et al.* Influenza Transmission Dynamics in Urban Households,
Managua, Nicaragua, 2012–2014. *Emerg Infect Dis* 24, 1882–1888 (2018).

575 34. World Health Organization. WHO manual on animal influenza diagnosis and 576 surveillance. (2002).

577 35. World Health Organization. WHO information for the molecular detection of 578 influenza viruses. (2020).

36. Centers for Disease Control and Prevention. CDC Real-time RT-PCR (rRT-PCR)
Protocol for Detection and Characterization of Influenza – Influenza A and Influenza B.

58137.Ghani, A. *et al.* The Early Transmission Dynamics of H1N1pdm Influenza in the582United Kingdom. *PLoS Curr* 1, RRN1130 (2010).

583 38. Carrat, F. *et al.* Time lines of infection and disease in human influenza: a review 584 of volunteer challenge studies. *Am J Epidemiol* **167**, 775–785 (2008).

39. Tsang, T. K., Lau, L. L. H., Cauchemez, S. & Cowling, B. J. Household
Transmission of Influenza Virus. *Trends in Microbiology* 24, 123–133 (2016).

587 40. Tsang, T. K. *et al.* Association Between Antibody Titers and Protection Against
588 Influenza Virus Infection Within Households. *The Journal of Infectious Diseases* 210,
589 684–692 (2014).

41. Cauchemez, S. *et al.* Household Transmission of 2009 Pandemic Influenza A
(H1N1) Virus in the United States. *New England Journal of Medicine* 361, 2619–2627
(2009).

593 42. Nishiura, H. & Inaba, H. Estimation of the incubation period of influenza A (H1N1-594 2009) among imported cases: Addressing censoring using outbreak data at the origin of 595 importation. *Journal of Theoretical Biology* **272**, 123–130 (2011). 596 43. Nishiura, H. Early efforts in modeling the incubation period of infectious diseases 597 with an acute course of illness. *Emerg Themes Epidemiol* **4**, 2 (2007).

598 44. Virlogeux, V. *et al.* Estimating the Distribution of the Incubation Periods of Human
599 Avian Influenza A(H7N9) Virus Infections. *American Journal of Epidemiology* **182**, 723–
600 729 (2015).

601 45. Markov Chain Monte Carlo in Practice. (Chapman and Hall/CRC, New York,

602 1995). doi:10.1201/b14835.